AIM ImmunoTech (AIM) Stock Price, News & Analysis

Company Overview

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats. AIM ImmunoTech has collaborated with government agencies and academic institutions to support its clinical development, leveraging these partnerships to access specialized expertise and streamline regulatory pathways.

Headquartered in Ocala, Florida, AIM ImmunoTech conducts its research and manufacturing operations in the United States, while seeking to establish strategic collaborations that extend its global reach. The company’s management team comprises experienced professionals in biotechnology development, regulatory affairs and commercial strategy, with a shared commitment to bringing novel immunotherapeutic solutions to market.

Key Stats

• Today's Range: $2.50 to $2.66
• 50-Day Range: $2.36 to $9.36
• 52-Week Range: $2.33 to $36.00
• Volume: 36,956 shs
• Average Volume: 64,661 shs
• Market Capitalization: $6.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $275.00
• Consensus Rating: Strong Buy

AIM ImmunoTech Stock Analysis - MarketRank™

AIM ImmunoTech scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Strong Buy

Consensus Rating

AIM ImmunoTech has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

AIM ImmunoTech has a consensus price target of $275.00, representing about 10,726.8% upside from its current price of $2.54.

Amount of Analyst Coverage

AIM ImmunoTech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for AIM ImmunoTech are expected to decrease in the coming year, from ($0.30) to ($0.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AIM ImmunoTech is -5.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AIM ImmunoTech is -5.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AIM ImmunoTech has a P/B Ratio of 12.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.61% of the float of AIM ImmunoTech has been sold short.

Short Interest Ratio / Days to Cover

AIM ImmunoTech has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AIM ImmunoTech does not currently pay a dividend.

Dividend Growth

AIM ImmunoTech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.61% of the float of AIM ImmunoTech has been sold short.

Short Interest Ratio / Days to Cover

AIM ImmunoTech has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 1.4 / 5
• News Sentiment: 0.60

News Sentiment

AIM ImmunoTech has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for AIM ImmunoTech this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for AIM on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added AIM ImmunoTech to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AIM ImmunoTech insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.02% of the stock of AIM ImmunoTech is held by insiders.

Percentage Held by Institutions

Only 12.02% of the stock of AIM ImmunoTech is held by institutions.

AIM Stock Analysis - Frequently Asked Questions

How have AIM shares performed this year?

AIM ImmunoTech's stock was trading at $19.80 at the start of the year. Since then, AIM shares have decreased by 87.2% and is now trading at $2.54.

How were AIM ImmunoTech's earnings last quarter?

AIM ImmunoTech Inc. (NYSE:AIM) announced its earnings results on Wednesday, November, 15th. The company reported ($16.00) EPS for the quarter, missing analysts' consensus estimates of ($11.00) by $5.00. The company earned $0.05 million during the quarter. AIM ImmunoTech had a negative net margin of 12,594.21% and a negative trailing twelve-month return on equity of 421.73%.

When did AIM ImmunoTech's stock split?

AIM ImmunoTech's stock reverse split on Thursday, June 12th 2025.The 1-100 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 11th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Who are AIM ImmunoTech's major shareholders?

AIM ImmunoTech's top institutional investors include Corient Private Wealth LLC (1.31%). Insiders that own company stock include Thomas K Equels, Peter W Rodino III, Stewart Appelrouth and Nancy Bryan.
View institutional ownership trends.

How do I buy shares of AIM ImmunoTech?

Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AIM ImmunoTech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), iBio (IBIO), Vaxart (VXRT), Meta Platforms (META), Sorrento Therapeutics (SRNE), NIO (NIO) and T2 Biosystems (TTOO).

Company Calendar

• Last Earnings: 11/15/2023
• Today: 9/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:AIM
• CIK: 946644
• Web: aimimmuno.com
• Phone: (352) 448-7797
• Fax: 215-988-1739
• Employees: 20
• Year Founded: 1990

Price Target and Rating

• Average Price Target for AIM ImmunoTech: $275.00
• High Price Target: $450.00
• Low Price Target: $100.00
• Potential Upside/Downside: +10,726.8%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($24.68)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$28.96 million
• Net Margins: -12,594.21%
• Pretax Margin: -12,594.21%
• Return on Equity: -421.73%
• Return on Assets: -147.54%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 0.75
• Quick Ratio: 0.75

Sales & Book Value

• Annual Sales: $121 thousand
• Price / Sales: 56.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.20 per share
• Price / Book: 12.70

Miscellaneous

• Outstanding Shares: 2,709,000
• Free Float: 68,740,000
• Market Cap: $6.88 million
• Optionable: Not Optionable
• Beta: 0.98